A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Assess the Efficacy and Safety of Ketotransdel in the Treatment of Pain Associated with Mild to Moderate Acute Soft Tissue Injury

Trial Profile

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Assess the Efficacy and Safety of Ketotransdel in the Treatment of Pain Associated with Mild to Moderate Acute Soft Tissue Injury

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2014

At a glance

  • Drugs Ketoprofen (Primary)
  • Indications Acute pain; Musculoskeletal pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Imprimis Pharmaceuticals
  • Most Recent Events

    • 02 Sep 2010 Primary endpoint results presented at the 13th World Congress on Pain
    • 02 Sep 2010 Results from the final data were presented at the 13th World Congress on Pain in Montreal, Canada, according to a Transdel Pharmaceuticals media release.
    • 25 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top